The Caledonian-Record

Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical ...

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, ...
The Caledonian-Record

Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UKCompany achieves positive ...
Nasdaq

Autolus Therapeutics plc to Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

Autolus Therapeutics plc, a biopharmaceutical company focused on next-generation programmed T cell therapies, announced that it will release its fourth quarter and full year 2024 financial results on ...
JD Supra

FDA approves CAR-T Cell Therapy for Refractory B-cell Precursor Acute Lymphoblastic Leukemia

On November 8, 2024 Autolus, Inc. (“Autolus”) announced that the FDA has approved AUCATZYL (obecabtagene autoleucel) for the treatment of adult patients with relapsed or refractory B-cell precursor ...
MarketWatch

Blackstone to invest up to $250 million in British biotech company Autolus

Blackstone Inc. is investing as much as $250 million in U.K. biotechnology company Autolus Therapeutics PLC to fund the final stages of development of a new therapy to treat a serious form of leukemia ...
Nasdaq

What Kind Of Shareholders Hold The Majority In Autolus Therapeutics plc's (NASDAQ:AUTL) Shares?

If you want to know who really controls Autolus Therapeutics plc (NASDAQ:AUTL), then you'll have to look at the makeup of its share registry. Institutions often own shares in more established ...
FierceBiotech

Autolus Appoints Chief Executive Officer—Dr. Christian Itin, Pioneer Of T-Cell Targeting Therapeutics, Takes The Helm Of Europe's Leading Engineered T-Cell Developer

London, 3 March 2016 – Autolus Limited ("Autolus"), a biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies for haematological and ...
BioWorld

Biontech and Autolus collaborate to advance their CAR T programs

Autolus Therapeutics Inc. has picked up plenty of financial momentum, about $600 million worth, in its runup to a November 2024 PDUFA date for its CD19 CAR T therapy. Helping propel that momentum is ...
Investing

First patient dosed in Autolus’ phase 1 trial for multiple sclerosis

LONDON/GAITHERSBURG - Autolus Therapeutics plc (NASDAQ:AUTL), a $431 million market cap biotech company, announced Monday that the first patient has been dosed in its Phase 1 BOBCAT trial evaluating ...

Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the ...
Business Insider

Autolus Therapeutics Enters Lease with Alexandria Real Estate Equities, Inc. for Future Commercial-Scale Manufacturing Site and U.S. Headquarters

LONDON, Jan. 14, 2019 /PRNewswire/ -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that ...
Wall Street Journal

Blackstone to Invest Up to $250 Million in Autolus Therapeutics of U.K.

Blackstone Inc.BX-2.56%decrease; red down pointing triangle is investing as much as $250 million in U.K. biotechnology company Autolus Therapeutics PLCAUTL 6.88%increase; green up pointing triangle to ...